3
Announcements
Trials
Browse
Landscape
Status
No longer available
1
Sponsor Class
INDUSTRY
1
Study Type
Expanded_access
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Multiple Myeloma
20
Melanoma
16
Prostatic Neoplasms
15
Neoplasms
15
Recurrence
13
Carcinoma, Non-Small-Cell Lung
13
Leukemia, Myeloid, Acute
12
Glioblastoma
11
Precursor Cell Lymphoblastic Leukemia-Lymphoma
8
Lymphoma
8
Glioma
7
Breast Neoplasms
7
Sarcoma
6
Neuroblastoma
6
Lung Neoplasms
6
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
6
Leukemia
6
Pancreatic Neoplasms
5
Lymphoma, Non-Hodgkin
5
Lambert-Eaton Myasthenic Syndrome
5
Gastrointestinal Stromal Tumors
5
Colorectal Neoplasms
5
Carcinoma, Renal Cell
5
Carcinoma, Hepatocellular
5
Triple Negative Breast Neoplasms
4
Neuroendocrine Tumors
4
Liver Neoplasms
4
Hodgkin Disease
4
Precancerous Conditions
3
Pheochromocytoma
3
Interventions
osimertinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
No longer available
×
Expanded_access
×
EGFR T790M Mutation Positive NSCLC
×
Clear all
NCT02451852
2016-07-14
AZD9291 US Expanded Access Program
AstraZeneca
No longer available